Skip to main content
. 2022 Sep 15;81(12):1661–1668. doi: 10.1136/ard-2022-222630

Figure 1.

Figure 1

Gatekeeping strategy. pSup, q2w and pSup, q4w represent p values from a one-sided test of superiority vs placebo for OKZ dose regimens 64 mg q2w and q4w, respectively. ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28 (CRP), Disease Activity Score 28 based on CRP; HAQ-DI, Health Assessment Questionnaire Disability Index; OKZ, olokizumab; q2w, every 2 weeks; q4w, every 4 weeks; Wk, week.